Why Perrigo (PRGO) Is Down 8.3% After Class Action Over Alleged Formula Business Misstatements

Simply Wall St.11-22

On November 18, 2025, Glancy Prongay & Murray LLP announced that it had filed a class action lawsuit against Perrigo Company plc in the U.S. District Court for the Southern District of New York, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585796371?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2025-11-22 15:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585796371","market":"us","top_or_hot":-1,"title":"Why Perrigo (PRGO) Is Down 8.3% After Class Action Over Alleged Formula Business Misstatements","media":"Simply Wall St.","content":"<div>\n<p>On November 18, 2025, Glancy Prongay & Murray LLP announced that it had filed a class action lawsuit against Perrigo Company plc in the U.S. District Court for the Southern District of New York, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/why-perrigo-prgo-is-down-83-after-class-action-over-alleged\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Perrigo (PRGO) Is Down 8.3% After Class Action Over Alleged Formula Business Misstatements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Perrigo (PRGO) Is Down 8.3% After Class Action Over Alleged Formula Business Misstatements\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-22 15:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/why-perrigo-prgo-is-down-83-after-class-action-over-alleged><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On November 18, 2025, Glancy Prongay & Murray LLP announced that it had filed a class action lawsuit against Perrigo Company plc in the U.S. District Court for the Southern District of New York, ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/why-perrigo-prgo-is-down-83-after-class-action-over-alleged\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRGO","symbol_name":"百利高","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/why-perrigo-prgo-is-down-83-after-class-action-over-alleged","article_id":"2585796371","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/why-perrigo-prgo-is-down-83-after-class-action-over-alleged","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2585796371","pubTimestamp":1763796093,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"On November 18, 2025, Glancy Prongay & Murray LLP announced that it had filed a class action lawsuit against Perrigo Company plc in the U.S. District Court for the Southern District of New York, alleging materially misleading statements and disclosure failures related to Perrigo's infant formula business acquired from Nestlé.\nThis lawsuit raises significant concerns about historical underinvestment, manufacturing deficiencies, and the accuracy of prior financial reporting by Perrigo, which...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRGO":"百利高","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4007":"制药"},"translate_title":"为什么Perrigo(PRGO)因涉嫌配方奶粉业务错误陈述而提起集体诉讼后股价下跌8.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGO":1.5},"content_text":"On November 18, 2025, Glancy Prongay & Murray LLP announced that it had filed a class action lawsuit against Perrigo Company plc in the U.S. District Court for the Southern District of New York, alleging materially misleading statements and disclosure failures related to Perrigo's infant formula business acquired from Nestlé. This lawsuit raises significant concerns about historical underinvestment, manufacturing deficiencies, and the accuracy of prior financial reporting by Perrigo, which may impact investor confidence in management transparency. We will examine how allegations of undisclosed operational risks in the infant formula business reshape the company's investment narrative. Rare earth metals are the new gold rush. Find out which 36 stocks are leading the charge.AdvertisementPerrigo Investment Narrative Recap Being a Perrigo shareholder rests on believing in the company’s capacity to rebound through self-care innovation, private label growth, and operational efficiency, even amid industry challenges. The recent class action lawsuit concerning alleged past disclosure failures in the infant formula business directly intensifies the spotlight on management transparency, the current key risk potentially impacting near-term trust and the ongoing strategic review’s impact on recovery efforts.\n  Of all recent developments, Perrigo’s November 6 announcement of a strategic review of its infant formula business is especially relevant here. This move aligns with immediate pressure on the company to address operational deficiencies and clarify the business’s future, directly intersecting with investor concerns triggered by the lawsuit.\n  Yet, against the potential for turnaround, investors should also consider the impact of increased supply chain and product quality risks lurking beneath the surface…\n Read the full narrative on Perrigo (it's free!)Perrigo's narrative projects $4.6 billion revenue and $183.6 million earnings by 2028. This requires 1.7% yearly revenue growth and a $243.1 million increase in earnings from -$59.5 million currently.Uncover how Perrigo's forecasts yield a $21.50 fair value, a 70% upside to its current price.Exploring Other PerspectivesPRGO Community Fair Values as at Nov 2025  Four estimates from the Simply Wall St Community place Perrigo's fair value between US$21.50 and US$55.05 per share. Despite optimism for longer term profit growth, the recent lawsuit raises pointed questions around earnings quality and transparency, underscoring the importance of weighing every viewpoint.\nExplore 4 other fair value estimates on Perrigo - why the stock might be worth just $21.50!Build Your Own Perrigo NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Perrigo research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Perrigo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Perrigo's overall financial health at a glance.Ready For A Different Approach?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585796371","isCrawlerRequest":true}